Company

Atriva Therapeutics

As of the edition of 20 October 2026, Atriva Therapeutics runs 1 drug; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

Status	Count
Stopped	1
Total	1

Status

Count

Stopped

Total

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
Target	Route
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2	Route A
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1	Route A

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.